Key facts
- It has raised $34.6M; the latest was Later Stage VC ($11.0M) in Apr 2026.
- Notable investors include Holbrook Angels, Over-the-Rhine Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Orthogon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Orthogon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orthogon Therapeutics
Developer of drug design therapeutics intended to meet critical needs in the translation of drug discovery by bridging frontier research with formal drug development. The company leverages a constellation of innovative technologies to discover and develop small molecules that modulate challenges to sought-after drug targets, enabling clients to efficiently produce high-quality medicinal lead molecules that can be developed in a partnership model.
- Sector
- Healthcare
- HQ
- Canton, MA, United States
- Founded
- 2012
- Employees
- 3
- Website
- orthogontherapeutics.com/
- Ownership
- Privately Held (backing)
Orthogon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orthogon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orthogon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.